When cells become tumor cells, their metabolism changes fundamentally. Researchers at the University of Basel and the University Hospital Basel have now demonstrated that this change leaves traces that could provide targets for cancer immunotherapies.
First Therapy Approved for Ultra-Rare Bone Disorder
The FDA approved the oral retinoid palovarotene (Sohonos) for treating abnormal bone growth associated with fibrodysplasia ossificans progressiva (FOP), drugmaker Ipsen announced on Wednesday. Palovarotene,
August 17, 2023